A Phase 3 interventional study of BT097 in Congenital Cytomegalovirus Infection, sponsored by Biotest. Terminated at 5 sites in Germany. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-03-10.
Sponsored by Biotest (part of Grifols) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Cytomegalovirus Infections with a site in Germany — 1 open to participants now, 1 under way, 1 of them phase 3. Cytomegalovirus Infections · Germany.
Among the 16 studies in Cytomegalovirus Infections with a site in Germany, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 8 in phase 3, and was the 16th registered.
370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.
Browse Cytomegalovirus Infections studies →1 of the 16 studies in Cytomegalovirus Infections with a site in Germany is open now. Recruiting first, the newest first:
Tobias Feuchtinger · Sites in Germany, Belgium, France and 3 more countries
Ages 2 mo+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 9 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2021.
This study's enrollment of 48 is below the median of 64 across 240 interventional studies indexed under Cytomegalovirus Infections.
Median enrollment 149 across the 13 interventional studies, 263 across the 2 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Biotest, one of the names counted as Grifols. Under that name alone:
Biotest is the lead sponsor of 14 studies on the registry; 1 is open to participants now.
Grifols has 1 study filed under Cytomegalovirus Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Cytomegalovirus Infections with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A phase 3, open-label, single-arm, prospective, multi-center trial of Cytotect CP Biotest (BT097) for prevention of maternal-fetal CMV transmission after primary maternal CMV infection. The main purpose of the trial is to demonstrate efficacy and safety of Cytotect CP Biotest in preventing maternal-fetal transmission of cytomegalovirus (CMV).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17
Drug: BT097
Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17
Also known as: Cytotect CP Biotest 100 U/mL solution for infusion
To determine the overall rate of maternal-fetal transmission at the time of amniocentesis (week 20 [-1 week / +2 weeks] of gestation)
To determine the overall rate of maternal-fetal transmission at the time of amniocentesis
Time frame: Gestational week 19 - week 22
Subgroups: (1) Subjects with periconceptionally acquired infection or (2) Subjects with infection acquired during first trimester
To determine the rate of maternal-fetal transmission at the time of amniocentesis
Time frame: Gestational week 20 +-1 Week
To determine maternal CMV viral load (copies/ml)
Number of CMV-DNA copies (copies/mL) and corresponding absolute and percentage changes from baseline, until gestational week (GW) 30
Time frame: until gestational week 30
To determine maternal anti-CMV IgG Levels (U/ml)
Maternal anti-CMV IgG Levels (U/ml), absolute and percentage changes from baseline
Time frame: until gestational week 30
To determine maternal anti-CMV IgG avidity (%)
Number/percentage of subjects with Low, Intermediate, High avidity
Time frame: until gestational week 30
To determine maternal anti-CMV IgM index (Index)
Number/percentage of subjects with non-reactive, indeterminate and reactive cut-off index (COI)
Time frame: until gestational week 30
To determine soluble fms-like tyrosine kinase 1 (sFlt-1) concentration in maternal serum
Number/percentage of subjects with high (≥1504 pg/mL) or low (\<1504 pg/mL) values
Time frame: until gestational week 30
To evaluate vitality of the fetuses/newborns
Number/percentage of subjects with Normal / Abnormal Not Clinically Significant / Abnormal Clinically Significant results per parameter and visit
Time frame: until date of delivery
To evaluate growth of the fetuses/newborns
Number/percentage of subjects with Normal / Abnormal Not Clinically Significant / Abnormal Clinically Significant results per parameter and visit
Time frame: Until date of delivery
To evaluate the rate of congenital CMV infection at delivery or within the first 3 days after delivery
To evaluate the rate of congenital CMV infection at delivery or within the first 3 days after delivery
Time frame: Date of Delivery + 3 days
To measure the number of CMV-DNA copies in the urine of newborns
To measure the number of CMV-DNA copies in the urine of newborns
Time frame: Date of Delivery
To assess the number, severity, causality, outcome, and seriousness of all adverse events (AEs)/ treatment-emergent AEs (TEAEs)/ AEs of special interest until delivery (+3 days) in both mother and fetus/newborn
To assess the number, severity, causality, outcome, and seriousness of all adverse events (AEs)/ treatment-emergent AEs (TEAEs)/ AEs of special interest until delivery (+3 days) in both mother and fetus/newborn
Time frame: Date of Delivery + 3 days
Ran from Nov 2021 to primary completion in Nov 2023, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.